Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease

Abstract

Lamivudine and entecavir are both efficacious in the prophylaxis of hepatitis B reactivation. Entecavir should be used in preference to lamivudine in patients CHB with detectable baseline HBV DNA levels.

Comparison between Entecavir and Lamivudine as Hepatitis B Reactivation Prophylaxis in Cancer Patient with Chemotherapy

“…Outcome of those study was HBV reactivation percentage (by assessing HBV DNA HBV related hepatitis (0% vs. 12.4%, p = 0.24) were of HVB were clinically lower in entecavir group than lamivudine group (11.8% vs. 20.2%), but statistically 3 In the study by Chen et al, subject with undetected HBV DNA at the beginning of therapy, both entecavir and lamivudine were effectively the same. 7 Otherwise, in subject with detected HBV DNA at the beginning of therapy, entecavir therapy showed no hepatitis B reactivation, while one from six patient from lamivudine group were having hepatitis B were more effective than lamivudine. It also can be for hepatitis B prophylaxis in HBsAg negative and immune control phase with undetected HBV DNA patients.…”

“…Resolute infection marked as antiHBc detected without anti-HBs. 7 HBV reactivation prevention could reduce mortality of HBV infection and could reduce chemotherapy dosage caused by HBV reactivation. 10 Lamivudine were HBV reactivation prophylaxis that recommended in many guidelines.…”

“…3 Entecavir were HBV DNA polymerase inhibitor selective that have an ability to inhibit viral replication, optimize histologica repair, reduce chronic hepatitis B progression, and lower resistance rate rather than lamivudine. 7 As this reason, entecavir were widely used as chronic hepatitis B therapy in Japan, replacing lamivudine since 2000. 13,14 But, there were few studies to investigate its effect as hepatitis B reactivation prophylaxis in chemotherapy patients.…”

“…7 The role of lamivudine as prophylaxis has been widely proofed in various clinical trial and was recommended in many guidelines. Otherwise, lamivudine as long term hepatitis therapy were restricted as recently found a hepatitis B virus that is resistance to lamivudine.…”

“…HBV related hepatitis were during six months post chemotherapy without any sign of acute viral hepatitis or any other systemic infections. 3,7 Li HR reported an incidence rate of hepatitis (5.9% vs 27%; p = 0.007), stopped chemotherapy cycle because of hepatitis (5.9% vs. 20.2%; p = 0.042), and …”